ASX Penny Stocks To Consider In February 2025

In This Article:

The Australian market has recently seen mixed performance, with the ASX200 closing slightly down by 0.11% at 8,511 points. Despite some sectors facing declines, IT and Staples have shown resilience, highlighting potential opportunities for investors exploring beyond traditional large-cap stocks. Penny stocks, though an older term, continue to attract attention as they often represent smaller or newer companies that can offer unique growth prospects when backed by solid financials.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.77

A$142.2M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.57

A$66.88M

★★★★★★

SHAPE Australia (ASX:SHA)

A$3.00

A$247.08M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.495

A$310.07M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.92

A$104.82M

★★★★★★

Dusk Group (ASX:DSK)

A$1.065

A$65.38M

★★★★★★

GTN (ASX:GTN)

A$0.56

A$108.99M

★★★★★★

Helloworld Travel (ASX:HLO)

A$2.04

A$324.82M

★★★★★★

IVE Group (ASX:IGL)

A$2.19

A$342.3M

★★★★☆☆

SKS Technologies Group (ASX:SKS)

A$1.59

A$246.55M

★★★★★★

Click here to see the full list of 1,032 stocks from our ASX Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Tissue Repair

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tissue Repair Ltd (ASX:TRP) is a clinical stage biopharmaceutical company focused on developing advanced wound healing products for chronic wounds and cosmetic procedure aftercare in Australia, with a market cap of A$18.74 million.

Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, amounting to A$1.79 million.

Market Cap: A$18.74M

Tissue Repair Ltd, a clinical-stage biopharmaceutical company, is currently pre-revenue with limited revenue of A$2 million. Despite this, the company maintains a strong cash position with short-term assets of A$19.4 million exceeding both its long-term (A$13.8K) and short-term liabilities (A$1.3M), providing a cash runway for over three years even if free cash flow declines at historical rates. While unprofitable and experiencing declining earnings over the past five years, it remains debt-free and has seen reduced volatility in its stock price recently. However, the board's lack of experience might be a concern for potential investors.

ASX:TRP Debt to Equity History and Analysis as at Feb 2025
ASX:TRP Debt to Equity History and Analysis as at Feb 2025

Venus Metals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Venus Metals Corporation Limited is involved in the exploration of mineral tenements in Western Australia and has a market capitalization of A$14.32 million.